SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Trends in Prescription Drug Launch Prices, 2008-2021
2 references·3 citing·15 second hop
Trends in Prescription Drug Launch Prices, 2008-2021 (2022)Trends in Prescription Drug Launch Prices…Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018 (2020)Changes in List Prices, Net P…The High Cost of Prescription Drugs in the United States (2016)The High Cost of Prescription…Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis (2024)Population-health impact of n…The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review (2023)The association between cost …High drug prices are not justified by industry’s spending on research and development (2023)High drug prices are not just…Diagnosing the decline in pharmaceutical R&D efficiency (2012)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies (2019)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)Pharmaceutical Research and Development: What Do We Get for All that Money? (2012)The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment (2013)Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions (2011)Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia (2013)Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents (2017)Net Health Benefits (1998)Methods for the Economic Evaluation of Health Care Programmes (2005)The NICE Cost-Effectiveness Threshold (2008)Health Costs And Financing: Challenges And Strategies For A New Administration (2021)
this work references cited by second hop

References

  • 2016The High Cost of Prescription Drugs in the United States591 cited
  • 2020Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018193 cited

Cited by

  • 2024Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis85 cited
  • 2023High drug prices are not justified by industry’s spending on research and development53 cited
  • 2023The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review48 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work